Health Canada warns against unauthorized injectable peptides
Health Canada issued a formal public advisory on April 9, 2026, warning against buying or injecting unauthorized peptides online, naming BPC-157 and TB-500.
May 9, 2026 · 3 min read
Health Canada issued a formal public advisory on April 9, 2026, telling Canadians to "think twice" before injecting peptides purchased online, citing contamination risks, lack of quality controls, and the absence of clinical evidence for safety or efficacy. The advisory specifically named BPC-157 and TB-500 among the unauthorized injectable drugs regulators have encountered through market surveillance and seizures.
What happened
The Health Canada advisory was triggered by an uptick in Canadians self-administering injectable peptides sourced from unregulated online vendors, often marketed for anti-aging, bodybuilding, or general "wellness." The agency stressed that none of these products carry an authorized drug identification number — the 8-digit DIN required for any drug legally sold in Canada — meaning they have not been assessed for safety, efficacy, or manufacturing quality.
Separately from the public advisory, Health Canada conducted enforcement actions, including the seizure of unauthorized injectable peptide drugs sold by Canada Peptide and from Optimum Wellness Centre in Calgary, Alberta. Both seizures are documented in the Health Canada recalls and safety alerts database. The agency noted that injectable drugs manufactured without oversight may contain incorrect concentrations, microbial contamination, or undisclosed additives.
The advisory is not a standalone event. It follows a pattern of Canadian regulators escalating scrutiny of the same supply chains that U.S. regulators have been monitoring through FDA warning letters and the Category 2 compounding restrictions that were only recently lifted in the United States.
Why it matters
Health Canada's advisory illustrates the core access dilemma that affects the entire strength-peptide space on both sides of the border. The peptides most widely used for recovery and performance — BPC-157, TB-500, and similar compounds — lack approved formulations in any major jurisdiction. Researchers, athletes, and patients who want them currently have no regulated channel to obtain them safely in Canada or the U.S.
The risks Health Canada flags are real and independent of the peptides' potential therapeutic value. Sterility failures and inconsistent dosing are common quality-control problems in the research-chemical market, as documented in third-party testing. This is not an argument that BPC-157 or TB-500 are inherently unsafe at the molecular level — preclinical data on both compounds is substantial — but a recognition that the current supply infrastructure does not offer the safeguards of a licensed pharmacy.
For context on the U.S. regulatory track, see our coverage of BPC-157 and the FDA's 503A compounding history and the upcoming PCAC review of seven peptides for compounding access.
What to watch
- Whether Health Canada issues formal guidance or a discussion paper on a pathway toward regulated access — as the FDA's July PCAC process creates precedent, Canadian regulators may follow
- Additional enforcement actions or seizures in the Canadian market
- Whether any Canadian physician associations issue position statements on how practitioners should approach patient inquiries about peptide use
- The College of Physicians & Surgeons of Alberta, which has flagged unauthorized injectable peptides separately, for any further provincial-level guidance
Sources
Sources